Increasing Survival in Stage III NSCLC: Optimizing Care and Addressing New Clinical Challenges

Watch this Webcast and download the slides from a CCO symposium at the 2019 CHEST Annual Meeting featuring experts in medical oncology, radiation oncology, and pulmonology discussing optimal integration of immune checkpoint inhibitors into the treatment of stage III NSCLC using a multidisciplinary approach.
Gerard A. Silvestri, MD, MS
Program Director
Kristin Higgins, MD
Mark A. Socinski, MD

Downloadable Slidesets

Download this slideset for a multidisciplinary expert–curated overview of stage III NSCLC, including insights on staging and standard-of-care chemoradiation strategies as well as an update on contemporary radiation techniques.

Gerard A. Silvestri, MD, MS
Program Director
Kristin Higgins, MD Mark A. Socinski, MD
Released: October 21, 2019

Download this slideset to review the latest clinical data supporting the optimal use of checkpoint inhibitor therapy in patients with stage III NSCLC, including expert guidance on management of immunotherapy-related pulmonary toxicity.

Gerard A. Silvestri, MD, MS
Program Director
Kristin Higgins, MD Mark A. Socinski, MD
Released: October 21, 2019

Download this slideset to gain insights from our multidisciplinary panel of experts on the optimal use of concurrent chemoradiation and checkpoint inhibition in the treatment of a series of case patients with stage III NSCLC.

Gerard A. Silvestri, MD, MS
Program Director
Kristin Higgins, MD Mark A. Socinski, MD
Released: October 21, 2019
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue